BioSpace News Archive

Smith+Nephew, the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgical innovation and training.

Bristol Myers Squibb announced new data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis were free of six-month confirmed disability progression.

InDex Pharmaceuticals Holding AB announced that 30% of patients have completed the final visit in Induction Study 1 of the phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis.

Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, announces positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met.

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.

AM-Pharma B.V. announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia patients.

BioCardia®, Inc. announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Sernova Corp. announced two oral presentations at the upcoming International Pancreas and Islet Transplant Association, International Xenotransplantation Association Cell Transplant & Regenerative Medicine Association joint congress taking October 26-29, 2023 in San Diego, CA.

AbbVie (NYSE: ABBV) today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.